报告题目：Analysis of the effects of the Btk inhibitor Ibrutinib on monocyte FcγR function
报 告 人：任 丽 （吉林大学）
报告时间：2018年11月1日（星期四）上午9:00
报告地点：独墅湖校区二期云轩楼2301室
报告人简介：
Li Ren held her PhD in Cell biology from Jilin University in June 2016. Her ph.D work in Jilin University identified a series of peptides with high affinity and selectivity to membrane type matrix metalloproteinases, these affinity peptides showed potential application to cancer diagnosis. She also focused on the elucidation of immune effects elicited by an irreversible Bruton’s tyrosine kinase inhibitor, ibrutinib, has shown efficacy against B-cell tumors. Currently, as a Postdoctoral Fellow, she focusing primarily on the development of mesoporous silica nanodrugs with synergistic effects of targeting/immunotherapy for overcoming drug resistance in cancer.
报告摘要：
The novel and irreversible tyrosine kinase inhibitor, ibrutinib, has shown significant activities across a variety of B-cell tumors such as Chronic Lymphocytic Leukemia (CLL) and B-cell Non-Hodgkin lymphoma, either alone or in combination with antibody therapy. Fcγ receptors (FcγR) on effector immune cells such as macrophages play an important role in tumor-specific antibody-mediated immune responses. Results suggested that combining ibrutinib with monoclonal antibodies can enhance B-CLL killing while not affecting macrophage effector function. Most importantly, local IFN-γ can overcome the inhibitory effects of ibrutinib through FcγR-mediated Erk phosphorylation. Furthermore, the study suggested that IFN-γ can re-educate nurse like cells and polarize them toward an effector-like state and that therapies promoting local IFN-γ production may be effective adjuvants for antibody therapy in CLL.